Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study
- PMID: 19589436
- DOI: 10.1016/j.jacc.2009.01.079
Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study
Abstract
Objectives: The purpose of this study was to characterize the prognosis of minimally symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM).
Background: Recent data have suggested that obstruction may be present in the majority of HCM patients, irrespective of cardiac symptoms. The prognosis of minimally symptomatic obstructive HCM remains poorly defined.
Methods: We examined 544 consecutive adult patients (age 59 +/- 16 years; 55% men) with obstructive HCM documented by Doppler echocardiography who were free of severe cardiac symptoms, and we performed clinical follow-up (median 9.3 years).
Results: There was only a slight excess mortality of the cohort in comparison to the expected survival of a similar U.S. general population (10-year observed vs. expected survival, 69.3% vs. 71.9%; p = 0.04) and 46% of the deaths were attributable to noncardiac causes. However, there was a clear relation between increasing severity of the left ventricular outflow tract (LVOT) gradient and outcome. For patients with high resting gradients (Doppler peak velocity >4 m/s), survival was significantly impaired (53% at 10 years; p = 0.001 vs. expected), and death or severe symptoms occurred in 68% of these patients within 10 years after the initial evaluation. Conversely, there was no impairment of long-term survival for patients with less-severe resting obstruction. Independent predictors of mortality in the entire cohort were age, prior stroke, and LVOT gradient severity.
Conclusions: Patients with obstructive HCM and mild or no symptoms have only slight excess mortality. However, patients with markedly elevated resting LVOT gradients are at a high risk of heart failure and death. These findings may have important implications for therapy, including the timing of septal reduction therapy.
Similar articles
-
Comparison of resting and exercise echocardiographic parameters as indicators of outcomes in hypertrophic cardiomyopathy.J Am Soc Echocardiogr. 2015 Feb;28(2):194-203. doi: 10.1016/j.echo.2014.10.001. Epub 2014 Nov 20. J Am Soc Echocardiogr. 2015. PMID: 25459499
-
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.J Am Coll Cardiol. 2005 Aug 2;46(3):470-6. doi: 10.1016/j.jacc.2005.02.090. J Am Coll Cardiol. 2005. PMID: 16053960
-
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.J Am Coll Cardiol. 2005 Aug 2;46(3):480-7. doi: 10.1016/j.jacc.2005.04.043. J Am Coll Cardiol. 2005. PMID: 16053962
-
The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.J Am Coll Cardiol. 2009 Jul 14;54(3):191-200. doi: 10.1016/j.jacc.2008.11.069. J Am Coll Cardiol. 2009. PMID: 19589431 Review.
-
Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard.Expert Rev Cardiovasc Ther. 2008 Jun;6(5):715-22. doi: 10.1586/14779072.6.5.715. Expert Rev Cardiovasc Ther. 2008. PMID: 18510487 Review.
Cited by
-
Complementary Role of Echocardiography and Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.Curr Cardiol Rep. 2017 Sep;19(9):81. doi: 10.1007/s11886-017-0897-z. Curr Cardiol Rep. 2017. PMID: 28752280 Review.
-
Effect of metoprolol in hypertrophic obstructive cardiomyopathy patients after alcohol septal ablation.Int J Cardiol Heart Vasc. 2023 Dec 2;49:101317. doi: 10.1016/j.ijcha.2023.101317. eCollection 2023 Dec. Int J Cardiol Heart Vasc. 2023. PMID: 38126007 Free PMC article.
-
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry.Circulation. 2024 Oct 22;150(17):1377-1390. doi: 10.1161/CIRCULATIONAHA.124.069378. Epub 2024 Oct 2. Circulation. 2024. PMID: 39355918
-
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.J Clin Med. 2023 Oct 19;12(20):6628. doi: 10.3390/jcm12206628. J Clin Med. 2023. PMID: 37892766 Free PMC article. Review.
-
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.CMAJ. 2013 Feb 5;185(2):127-34. doi: 10.1503/cmaj.120138. Epub 2012 Oct 29. CMAJ. 2013. PMID: 23109605 Free PMC article. Review. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources